Stock Analiz

Ernexa Therapeutics Inc. ERNA

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.68Market cap $3M
Open the interactive analysis →

Ernexa Therapeutics Inc. (ERNA) is a healthcare company listed in the US with a market value of about $3M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.0, a 5-year average ROIC of -286%.

About Ernexa Therapeutics

Ernexa Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $26M in 2014 to $582000 in 2024, a decline of about 31.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3000% over three years (dilution for shareholders).

Score: 0.8 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.0
Forward P/E—
P/FCF—
P/S—
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-378.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-19758.7%
ROIC (5-yr avg.)-285.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue—$582000$68000$0—$6M$20M$23M$21M$22M
Net income-$14M-$45M-$22M-$25M-$123M-$7M-$2M-$259000-$1M-$3M
Free cash flow-$7M-$16M-$20M-$21M-$24M-$8M$3M$717000-$179000-$404000
EPS (diluted)$-2.24$-48.96$-61.19$-120.87$-848.96$-122.99$-215.98$-30.00$-134989.03$-461962.47
Net margin—-7652.8%-31864.7%——-125.7%-10.3%-1.1%-5.1%-13.1%
ROIC-321.3%-519.2%-56.6%-213.2%-318.3%-61.1%-8.8%1.1%-10.4%-14.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Ernexa Therapeutics’s P/E ratio?

About 0.0, based on the last twelve months of diluted earnings per share.

Does Ernexa Therapeutics pay a dividend?

Not currently.

Is Ernexa Therapeutics a good stock to buy?

We do not give buy or sell advice. Ernexa Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.